Skip to main content
OpenTrials
Completed

NCT Number: NCT04628221

Open Label Study Using OsteoProbe System

Prospective, Single Center, Open Label Clinical Study. The purpose of the study is to collect safety data associated with the use of the OsteoProbe System. Study Duration is expected to take approximately 3 months from first subject enrolled to the last follow-up visit.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Meridian Clinical Research, LLC.

Omaha, Nebraska, 68134, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be greater than or equal to 22 years of age;
  • Be able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study
  • If female and of child-bearing potential, must have a negative pregnancy status.

Exclusion criteria

  • Active skin infection at the procedure site as identified during a SOC physical examination.
  • Subject-reported or known systemic infection;
  • Subject-reported or known allergy to local anesthetic;
  • Subject-reported or known allergy to stainless steel or nickel materials;
  • Subject-reported or known current use of systemic antibiotics, or topical antibiotics administered to the procedure site;
  • Subject-reported or known history of needle phobia;
  • Significant soft tissue at the procedure site which would preclude use of the OsteoProbe in the judgement of the Investigator;
  • Known instance of hardware in the tibia that is intended to be measured based on radiographic imaging;
  • Known instance of a previous or current fracture in the tibia that is intended to be measured based on radiographic imaging;
  • Are known to be actively participating or known to have participated in another clinical investigation for which they received an investigational product (including but not limited to a drug or vaccine) within the last 90 days, or reports that they intend to participate in another clinical investigation during the course of the study;
  • Are known to be currently abusing drugs or alcohol or have a known history of the same within the last 12 months;
  • Have any known or subject reported mental or psychological disorders that, in the judgement of the Investigator, would impair their ability to accurately complete the NRS Pain Score surveys;
  • Are currently a prisoner;
  • Have a condition which, in the judgement of the Investigator, would preclude adequate evaluation of the device's safety and performance. Conditions include but are not limited to:
  • Regional or systemic pain syndromes
  • Radicular pain syndromes
  • Chronic or intermittent leg pain
  • Migraine headaches

Treatment and study plan

OsteoProbe System

Device

The OsteoProbe® System ("OsteoProbe") is a bone microindentation measurement tool. The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision. There are no other available measurement tools for clinical assessment of bone's resistance to microindentation.

Primary outcomes

  1. The Number of Participants With Reported Device Related Serious Adverse Events.

    Time frame: Procedure

    The number of participants who experienced device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System, per potential risks in the protocol.

  2. The Number of Participants With Reported Device Related Serious Adverse Events.

    Time frame: 1-day follow up visit

    The incidence of device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System.

  3. The Number of Participants With Reported Device Related Serious Adverse Events.

    Time frame: 7-day follow up visit

    The incidence of device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System.

  4. The Number of Participants With Reported Device Related Serious Adverse Events.

    Time frame: 30-day follow up visit

    The number of participants who experienced device-related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe System, per potential risks in the protocol.

Secondary outcomes

  1. NRS Pain Scores

    Time frame: Post-procedure, 1-day, 7-day and 30-day follow up visits

    The Numeric Rating Scale (NRS) is a continuous scale comprised of a line, with an eleven point numeric range (0 to 10) anchored by 2 verbal descriptors, one for each symptom extreme. The 0 mark corresponds to 'no pain', while the 10 mark corresponds to 'worse pain possible'. Therefore, higher scores indicate greater pain intensity. At all follow-up time points (post-procedure, Day 1, Day 7 , and Day 30), average was taken compared to baseline (Pre-Procedure).

  2. BMSi Scores

    Time frame: Procedure

    BSMi Score is an output measure by the OsteoProbe device to measure bone tissue's resistance to microindentation which can be positively correlated with bone tissue quality.

  3. Number of Participants With Adverse Events

    Time frame: Procedure through day 30

    The number of participants who experienced an adverse event.

  4. Number of Participants With Device-related Adverse Events

    Time frame: Procedure through day 30

    The number of participants who experienced an device-related adverse event.

  5. Number of Participants With Serious Adverse Events

    Time frame: Procedure through day 30

    The number of participants who experienced a Serious adverse event.

  6. Unanticipated Adverse Device Effects (UADE)

    Time frame: Procedure through day 30

    The number of participants who experienced a Unanticipated adverse device effects.

Sponsors and collaborators

Lead sponsor

Active Life Scientific, Inc.

Industry

Collaborators

  • MCRA

Registry information

Official study title

A Single-Arm, Open Label Clinical Study to Collect Safety Data on the Osteoprobe System When Used as a Measurement Tool

Acronym: OP

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Nov 13, 2020
Registry last updated
Apr 27, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.